Radical Cure for P. vivax: One Dose or Fourteen Days
A returning traveler recovering from an acute P. vivax attack now needs radical cure therapy to clear the dormant liver hypnozoites that cause relapse. Tafenoquine offers a single dose against primaquine's real-world adherence problem over fourteen days — but it demands a stricter, slower G6PD test than primaquine ever has.
B.N., a 33-year-old marketing consultant, is three days out from the fevers, chills, and drenching sweats that sent him to urgent care after a two-week trip to Papua New Guinea for a friend's destination wedding — a trip he took chemoprophylaxis for faithfully, right up until the last week, when a stomach bug made him stop taking his pills rather than risk vomiting them back up. A thick smear confirmed Plasmodium vivax. Chloroquine would be the reflex almost anywhere else, but Papua New Guinea is one of only two places on the map — Indonesia is the other — where chloroquine-resistant P. vivax is confirmed and common enough that CDC directs treatment as though resistance were a given, so his destination, not his blood smear, is what took chloroquine off the table. Three days of artemether-lumefantrine have cleared his acute parasitemia and resolved his fevers. What's left is the part of vivax malaria that no blood-stage drug touches: dormant liver-stage hypnozoites, capable of reactivating months or years from now with no new mosquito bite required, and radical cure — killing those hypnozoites directly, not just the blood- stage parasites — is the only way to prevent that.
Two drugs can do this, and the choice between them is a real one. The traditional option, primaquine at a fourteen-day course, has decades of use behind it but a well-documented adherence problem — relapse driven not by the drug failing, but by patients quietly not finishing all fourteen days once they feel better, which B.N., by his own admission after describing how he handled his prophylaxis last week, seems like a real risk for. Tafenoquine, licensed for radical cure on the strength of the DETECTIVE and GATHER trials, offers a single 300mg dose with no adherence question at all. The catch is the screening it demands: primaquine has long been given after a simple qualitative G6PD screen, but tafenoquine's label requires quantitative testing, a result that reports actual enzyme activity level rather than a binary normal/deficient call — a real difference for female patients, who can carry intermediate activity as heterozygotes. B.N. is not in that group; as a man he is hemizygous, either deficient or not, so his normal qualitative screen is already close to the answer the quantitative assay will return. The delay he is being asked to accept buys confirmation of something his own genetics make unlikely to change.
The dose he'll actually finish, and the test that has to come first
I'd steer him toward tafenoquine. He just showed us, on this same trip, exactly the failure mode that drives most real-world primaquine relapse — stopping a medication early once he felt better. A single directly-observed dose removes that risk entirely, and as a male patient his quantitative result is very likely to land in the same normal range his qualitative screen already showed.
I wouldn't make this argument as strongly for a patient with no adherence red flags at all. He has one, and it's recent and specific to this exact clinical problem.
Primaquine has decades of outcome data behind it, and his qualitative G6PD screen already resulted normal — he could start today. Waiting five to seven days for a quantitative result to start tafenoquine instead means five to seven more days of unaddressed hypnozoites, which isn't a trivial trade against an adherence risk that structured counseling and a scheduled check-in can meaningfully reduce.
I don't think one missed week of prophylaxis on a trip he's already annoyed about is the same as a confident prediction he won't finish a fourteen-day antibiotic-style course when he understands what it's actually protecting against.
I don't think this has to be decided by us at all, honestly. Both of your arguments are real and roughly balanced — a genuine adherence risk against a genuine testing delay. Send the quantitative G6PD test today, give him structured primaquine-adherence counseling as a real bridge option in the meantime, and let him choose once he actually understands the trade-off himself.
He's the one who has to either take a pill for fourteen days or wait a week for a single dose. That's not a detail to route around, it's the actual deciding factor once the clinical case for both is this close.
Agreed: the quantitative G6PD test was sent, B.N. was given a clear, honest explanation of both options' actual trade-off — a week's wait for one dose versus starting today on a fourteen- day course he'd need real discipline to finish — and structured adherence counseling was provided as a bridge regardless of which drug he ultimately chooses. He left leaning toward waiting for tafenoquine, citing his own recent experience with the prophylaxis course directly.
All three voices signed off on the same plan, though not for identical reasons: the travel medicine physician was glad tafenoquine will likely be his choice; the infectious disease physician would still have counseled primaquine today if asked directly, and said so before deferring to B.N.'s own decision. The disagreement didn't need resolving once the choice genuinely became his to make.